Corcept Therapeutics Inc CORT
We take great care to ensure that the data presented and summarized in this overview for CORCEPT THERAPEUTICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CORT
View all-
Black Rock Inc. New York, NY16.8MShares$473 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.57MShares$269 Million0.0% of portfolio
-
Ingalls & Snyder LLC New York, NY8.3MShares$233 Million9.24% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny7.12MShares$200 Million0.28% of portfolio
-
Parallel Advisors, LLC3.82MShares$107 Million2.62% of portfolio
-
State Street Corp Boston, MA3.58MShares$100 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.57MShares$72.1 Million0.02% of portfolio
-
Novo Holdings Hellerup, G72.41MShares$67.7 Million4.93% of portfolio
-
Geode Capital Management, LLC Boston, MA2.16MShares$60.6 Million0.01% of portfolio
-
Norden Group LLC Provo, UT1.99MShares$55.8 Million0.56% of portfolio
Latest Institutional Activity in CORT
Top Purchases
Top Sells
About CORT
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Insider Transactions at CORT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 13
2024
|
Sean Maduck |
SELL
Open market or private sale
|
Direct |
50,000
-36.98%
|
$1,400,000
$28.0 P/Share
|
|
May 13
2024
|
Sean Maduck |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+26.99%
|
$150,000
$3.88 P/Share
|
|
May 09
2024
|
Joseph Douglas Lyon |
SELL
Open market or private sale
|
Direct |
7,227
-49.7%
|
$187,902
$26.0 P/Share
|
|
May 09
2024
|
Joseph Douglas Lyon |
BUY
Exercise of conversion of derivative security
|
Direct |
7,227
+33.2%
|
$79,497
$11.35 P/Share
|
|
May 02
2024
|
Joseph Douglas Lyon |
SELL
Open market or private sale
|
Direct |
10,830
-59.69%
|
$281,580
$26.0 P/Share
|
|
May 02
2024
|
Joseph Douglas Lyon |
BUY
Exercise of conversion of derivative security
|
Direct |
10,830
+37.38%
|
$119,130
$11.35 P/Share
|
|
May 01
2024
|
Daniel N Swisher Jr |
SELL
Open market or private sale
|
Direct |
2,200
-100.0%
|
$50,600
$23.09 P/Share
|
|
May 01
2024
|
Daniel N Swisher Jr |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+50.0%
|
$11,000
$5.86 P/Share
|
|
Apr 10
2024
|
David L Mahoney |
BUY
Other acquisition or disposition
|
Indirect |
27,806
+2.24%
|
-
|
|
Apr 10
2024
|
David L Mahoney |
SELL
Other acquisition or disposition
|
Direct |
27,806
-50.0%
|
-
|
|
Apr 10
2024
|
David L Mahoney |
SELL
Payment of exercise price or tax liability
|
Direct |
2,194
-7.31%
|
$50,462
$23.8 P/Share
|
|
Apr 10
2024
|
David L Mahoney |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+50.0%
|
$30,000
$1.74 P/Share
|
|
Apr 04
2024
|
Joseph Douglas Lyon |
SELL
Open market or private sale
|
Direct |
5,443
-42.67%
|
$141,518
$26.0 P/Share
|
|
Apr 04
2024
|
Joseph Douglas Lyon |
BUY
Exercise of conversion of derivative security
|
Direct |
5,443
+29.91%
|
$59,873
$11.35 P/Share
|
|
Apr 01
2024
|
Joseph Douglas Lyon |
SELL
Open market or private sale
|
Direct |
500
-6.4%
|
$13,000
$26.01 P/Share
|
|
Apr 01
2024
|
Joseph Douglas Lyon |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+6.01%
|
$5,500
$11.35 P/Share
|
|
Apr 01
2024
|
Daniel N Swisher Jr |
SELL
Open market or private sale
|
Direct |
2,200
-100.0%
|
$55,000
$25.3 P/Share
|
|
Apr 01
2024
|
Daniel N Swisher Jr |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+50.0%
|
$11,000
$5.86 P/Share
|
|
Mar 27
2024
|
Sean Maduck |
SELL
Open market or private sale
|
Direct |
25,953
-23.34%
|
$648,825
$25.01 P/Share
|
|
Mar 27
2024
|
Sean Maduck |
BUY
Exercise of conversion of derivative security
|
Direct |
25,953
+18.93%
|
$77,859
$3.88 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 28.4K shares |
|---|---|
| Bona fide gift | 38.9K shares |
| Exercise of conversion of derivative security | 498K shares |
| Other acquisition or disposition | 27.8K shares |
| Payment of exercise price or tax liability | 81.1K shares |
|---|---|
| Bona fide gift | 60.2K shares |
| Other acquisition or disposition | 28.8K shares |
| Open market or private sale | 377K shares |